Treatment‐free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure

Documenti analoghi

• Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients
  di: Vincent Alcazer, et al.
  Pubblicazione: (2024)
• Introducing a prognostic score for successful treatment‐free remission in chronic myeloid leukaemia
  di: Simone Claudiani, et al.
  Pubblicazione: (2026)
• Outcomes of Bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia in US veterans with severe renal dysfunction
  di: Chenyu Lin, et al.
  Pubblicazione: (2024)
• Real‐world comparative effectiveness of venetoclax‐obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia
  di: Nilanjan Ghosh, et al.
  Pubblicazione: (2024)
• Dynamic improvement of the treatment‐free remission prognostic score by prolonging MR4 duration in chronic myeloid leukaemia
  di: Mai Fujita, et al.
  Pubblicazione: (2026)